Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash & Current Investments (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash & Current Investments for 16 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments changed N/A to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 485.49% increase, with the full-year FY2025 number at $405000.0, down 66.19% from a year prior.
  • Cash & Current Investments was $1.1 million for Q3 2025 at IGC Pharma, up from $454000.0 in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $13.3 million in Q2 2021 to a low of $193000.0 in Q3 2022.
  • A 5-year average of $3.7 million and a median of $2.0 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 1569.43% in 2023, then tumbled 75.11% in 2025.
  • IGC Pharma's Cash & Current Investments stood at $13.3 million in 2021, then crashed by 62.21% to $5.0 million in 2022, then crashed by 35.98% to $3.2 million in 2023, then plummeted by 85.41% to $470000.0 in 2024, then soared by 140.43% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash & Current Investments are $1.1 million (Q3 2025), $454000.0 (Q2 2025), and $405000.0 (Q1 2025).